Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin. - Institut Pasteur Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2013

Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.

Abstract

Meningococcal gyrA gene sequence data, MICs, and mouse infection were used to define the ciprofloxacin breakpoint for Neisseria meningitidis. Residue T91 or D95 of GyrA was altered in all meningococcal isolates with MICs of ≥ 0.064 μg/ml but not among isolates with MICs of ≤ 0.032 μg/ml. Experimental infection of ciprofloxacin-treated mice showed slower bacterial clearance when GyrA was altered. These data suggest a MIC of ≥ 0.064 μg/ml as the ciprofloxacin breakpoint for meningococci and argue for the molecular detection of ciprofloxacin resistance.

Dates and versions

pasteur-02089320 , version 1 (03-04-2019)

Identifiers

Cite

Eva Hong, Sara Thulin Hedberg, Raquel Abad, Cecilia Fazio, Rocío Enríquez, et al.. Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.. Antimicrobial Agents and Chemotherapy, 2013, 57 (4), pp.1961-1964. ⟨10.1128/AAC.02184-12⟩. ⟨pasteur-02089320⟩

Collections

PASTEUR
87 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More